Danaher Corp.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $24.57B | $23.88B | $23.89B | $26.64B | $24.80B | $22.28B | $17.91B |
| Biotechnology | — | — | — | $7.03B | — | — | $0 | $0 |
| Life Sciences | — | — | — | $7.16B | — | — | $10.55B | $6.90B |
| Diagnostics | — | — | — | $8.09B | — | — | $7.40B | $6.56B |
| Dental | — | — | — | $0 | — | — | $0 | $0 |
| Environmental & Applied Solutions | — | — | — | $0 | — | — | $4.33B | $4.45B |
| Cost of Revenue | — | $10.05B | $9.67B | $9.86B | $10.46B | $9.56B | $9.81B | $7.93B |
| Gross Profit | — | $14.52B | $14.21B | $14.03B | $16.19B | $15.24B | $12.48B | $9.98B |
| Gross Margin | — | 59.1% | 59.5% | 58.7% | 60.8% | 61.4% | 56.0% | 55.7% |
| Operating Expenses | ||||||||
| Research & Development | — | $1.60B | $1.58B | $1.50B | $1.53B | $1.50B | $1.35B | $1.13B |
| SG&A Expense | — | $8.24B | $7.76B | $7.33B | $7.12B | $6.82B | $6.90B | $5.59B |
| Operating Income | — | $4.69B | $4.86B | $5.20B | $7.54B | $6.38B | $4.23B | $3.27B |
| Operating Margin | — | 19.1% | 20.4% | 21.8% | 28.3% | 25.7% | 19.0% | 18.3% |
| Interest Expense | — | — | — | $286.0M | $204.0M | $231.0M | $275.0M | $108.0M |
| Pretax Income | — | $4.23B | $4.65B | $5.04B | $7.15B | $6.51B | $4.50B | $3.31B |
| Income Tax Expense | — | $633.0M | $747.0M | $823.0M | $818.0M | $1.06B | $849.0M | $873.0M |
| Net Income | — | $3.61B | $3.90B | $4.76B | $7.21B | $6.43B | $3.65B | $3.01B |
| Net Margin | — | 14.7% | 16.3% | 19.9% | 27.1% | 25.9% | 16.4% | 16.8% |
| EPS (Basic) | — | $5.07 | $5.33 | $6.44 | $9.80 | $8.77 | $4.97 | $4.11 |
| EPS (Diluted) | — | $5.05 | $5.29 | $6.38 | $9.66 | $8.61 | $4.89 | $4.05 |
| Shares Outstanding (Basic) | 707.1M | 712.7M | 731.0M | 736.5M | 725.1M | 714.6M | 706.2M | 715.0M |
| Shares Outstanding (Diluted) | 707.1M | 716.1M | 737.2M | 743.1M | 737.1M | 736.8M | 718.7M | 725.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |